• Q7 Good Manufacturing Practice

    Code Document Title Previously coded
    • Finalised Guideline:
      November 2000

      Description :

      Early in the ICH Process it was agreed that there was adequate international agreement on the technical aspects of Good Manufacturing Practices (GMP) for Pharmaceutical Products and that further harmonisation action through ICH was not needed. Recently, however, attention has focused on the need to formalise GMP requirements for the components of pharmaceutical products - both active and inactive. In February 1998, the ICH Steering Committee agreed that GMP for Active Pharmaceutical Ingredients (APIs) should be adopted as an ICH Topic.

      When this topic was adopted, the Steering Committee took steps to ensure that due account was taken of the work already in progress by PIC/S, FDA, United States and other parties. In view of the unusually wide implications of this Topic, a much extended EWG has been established which includes, in addition to the six ICH parties and the Observers, experts representing IGPA (generics industry), WSMI (self medication industry) and PIC/S. With respect to the latter representatives from China, India and Australia have been invited to participate.

      Implementation :

      Step 5


      EC, EuropeAdopted by CPMP, November 2000, issued as CPMP/ICH/4106/00

      FDA, United States Published in the Federal Register, 25 September 2001, Vol. 66, No. 186, p. 49028-9

      Health Canada, Canada Implemented 7 December 2002, Guide GUI-0104

      MHLW/PMDA, Japan Adopted November 2001, PMSB/ELD Notification No. 1200

      Swissmedic, Switzerland - Refer to the press release on Swissmedic, Switzerland's website